4.6 Article

Increased AICD generation does not result in increased nuclear translocation or activation of target gene transcription

期刊

EXPERIMENTAL CELL RESEARCH
卷 314, 期 13, 页码 2419-2433

出版社

ELSEVIER INC
DOI: 10.1016/j.yexcr.2008.05.003

关键词

AICD; APP; neprilysin; KAI1; endosomes; lysosomes; Alzheimer's disease; NH4Cl

向作者/读者索取更多资源

A sequence of amyloid precursor protein (APP) cleavages culminates in the sequential release of the APP intracellular domain (AICD) and the amyloid beta peptide (A beta) and/or p3 fragment. one of the environmental factors favouring the accumulation of AICD appears to be a rise in intracellular pH. Here we further identified the metabolism and subcellular localization of artificially expressed constructs under such conditions. We also co-examined the mechanistic lead up to the AICD accumulation and explored possible significances for its increased expression. We found that most of the AICD generated under pH neutralized conditions is likely cleaved from C83. While the AICD surplus was unable to further activate transcription of a luciferase reporter via a Ga14-DNA-binding domain, it failed entirely via the endogenous promoter regions of proposed target genes, APP and KAI1. The lack of a specific transactivation potential was also demonstrated by the unchanged levels of target gene mRNA. However, rather than translocating to the nucleus, the AICD surplus remains membrane tethered or free in the cytosol where it interacts with Fe65. Therefore we provide strong evidence that an increase in AICD generation does not directly promote gene activation of previously proposed target genes. (c) 2008 Elsevier Inc. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Biochemistry & Molecular Biology

On the origin of BAG(3) and its consequences for an expansion of BAG3's role in protein homeostasis

Marius W. Baeken, Christian Behl

Summary: The BAG protein family, particularly BAG3, plays a crucial role in cellular protein homeostasis, with BAG3 being important in macroautophagy. Studies across different species have provided insights into the functions and regulations of BAG3 and other BAG proteins, but there is still a lack of research on the evolution of BAG3 and its phylogenetic position within the BAG family.

JOURNAL OF CELLULAR BIOCHEMISTRY (2022)

Article Biochemistry & Molecular Biology

Long-term caffeine treatment of Alzheimer mouse models ameliorates behavioural deficits and neuron loss and promotes cellular and molecular markers of neurogenesis

Martina Stazi, Sandra Lehmann, M. Sadman Sakib, Tonatiuh Pena-Centeno, Luca Buschgens, Andre Fischer, Sascha Weggen, Oliver Wirths

Summary: Research suggests that moderate caffeine consumption reduces the risk of Alzheimer's disease and can improve neuronal loss, behavioral deficits, and neurogenesis in mouse models of the disease. The study challenges the belief that caffeine is anti-amyloidogenic and highlights the potential role of promoting neurogenesis in its beneficial effects.

CELLULAR AND MOLECULAR LIFE SCIENCES (2022)

Article Clinical Neurology

Plasma biomarkers and genetics in the diagnosis and prediction of Alzheimer's disease

Joshua Stevenson-Hoare, Amanda Heslegrave, Ganna Leonenko, Dina Fathalla, Eftychia Bellou, Lauren Luckcuck, Rachel Marshall, Rebecca Sims, Bryan Paul Morgan, John Hardy, Bart de Strooper, Julie Williams, Henrik Zetterberg, Valentina Escott-Price

Summary: Plasma biomarkers for Alzheimer's disease-related pathologies have made significant progress in recent years, with well-validated blood tests available for the detection of amyloid and tau pathology, as well as neurodegeneration and astrocytic activation. This study demonstrates that a combination of five plasma biomarkers, along with genetic variants associated with these biomarkers, can be used to accurately diagnose and predict the onset of Alzheimer's disease.
Article Biochemistry & Molecular Biology

Meprin β knockout reduces brain Aβ levels and rescues learning and memory impairments in the APP/lon mouse model for Alzheimer's disease

Liana Marengo, Fred Armbrust, Caroline Schoenherr, Steffen E. Storck, Ulrich Schmitt, Silvia Zampar, Oliver Wirths, Hermann Altmeppen, Markus Glatzel, Christoph Kaether, Sascha Weggen, Christoph Becker-Pauly, Claus U. Pietrzik

Summary: This study reports the generation of a transgenic mouse model of AD lacking the functional Mep1b gene (APP/lon x Mep1b(-/-)). The results showed that when meprin beta is absent, the levels of A beta 1-40 and 1-42 are reduced in APP/lon mice, and the deposition of N-terminally truncated A beta 2-x peptide is also decreased. Importantly, the loss of meprin beta improved cognitive abilities in APP/lon mice.

CELLULAR AND MOLECULAR LIFE SCIENCES (2022)

Article Medicine, Research & Experimental

AAV-mediated delivery of an anti-BACE1 VHH alleviates pathology in an Alzheimer's disease model

Marika Marino, Lujia Zhou, Melvin Y. Rincon, Zsuzsanna Callaerts-Vegh, Jens Verhaert, Jerome Wahis, Eline Creemers, Lidia Yshii, Keimpe Wierda, Takashi Saito, Catherine Marneffe, Iryna Voytyuk, Yessica Wouters, Maarten Dewilde, Sandra Duque, Cecile Vincke, Yona Levites, Todd E. Golde, Takaomi C. Saido, Serge Muyldermans, Adrian Liston, Bart De Strooper, Matthew G. Holt

Summary: Single domain antibodies (VHHs) have potential therapeutic value for neurological disorders, but their use in the central nervous system is limited by the blood-brain barrier. This study proposes a gene transfer strategy using BBB-crossing AAV-based vectors to deliver VHH directly into the CNS. The results show that AAV-delivered VHH can effectively inhibit BACE1 and improve cognitive performance in an Alzheimer's disease mouse model, providing a novel therapeutic approach for neurodegenerative diseases.

EMBO MOLECULAR MEDICINE (2022)

Article Immunology

Astrocyte-targeted gene delivery of interleukin 2 specifically increases brain-resident regulatory T cell numbers and protects against pathological neuroinflammation

Lidia Yshii, Emanuela Pasciuto, Pascal Bielefeld, Loriana Mascali, Pierre Lemaitre, Marika Marino, James Dooley, Lubna Kouser, Stijn Verschoren, Vasiliki Lagou, Hannelore Kemps, Pascal Gervois, Antina de Boer, Oliver T. Burton, Jerome Wahis, Jens Verhaert, Samar Tareen, Carlos P. Roca, Kailash Singh, Carly E. Whyte, Axelle Kerstens, Zsuzsanna Callaerts-Vegh, Suresh Poovathingal, Teresa Prezzemolo, Keimpe Wierda, Amy Dashwood, Junhua Xie, Elien Van Wonterghem, Eline Creemers, Meryem Aloulou, Willy Gsell, Oihane Abiega, Sebastian Munck, Roosmarijn E. Vandenbroucke, Annelies Bronckaers, Robin Lemmens, Bart De Strooper, Ludo Van Den Bosch, Uwe Himmelreich, Carlos P. Fitzsimons, Matthew G. Holt, Adrian Liston

Summary: The ability of immune-modulating biologics to prevent and reverse pathology has transformed recent clinical practice. In this study, researchers identified brain interleukin 2 (IL-2) levels as a limiting factor for brain-resident T-reg cells and developed a gene-delivery approach to astrocytes to increase IL-2 production. Mice with brain-specific IL-2 delivery were protected against neuroinflammation, demonstrating the effectiveness of this approach.

NATURE IMMUNOLOGY (2022)

Article Clinical Neurology

CRISPR/Cas9 screen in human iPSC-derived cortical neurons identifies NEK6 as a novel disease modifier of C9orf72 poly(PR) toxicity

Wenting Guo, Haibo Wang, Arun Kumar Tharkeshwar, Julien Couthouis, Elke Braems, Pegah Masrori, Evelien Van Schoor, Yannan Fan, Karan Ahuja, Matthieu Moisse, Maarten Jacquemyn, Rodrigo Furtado Madeiro da Costa, Madhavsai Gajjar, Sriram Balusu, Tine Tricot, Laura Fumagalli, Nicole Hersmus, Rekin's Janky, Francis Impens, Pieter Vanden Berghe, Ritchie Ho, Dietmar Rudolf Thal, Rik Vandenberghe, Muralidhar L. Hegde, Siddharthan Chandran, Bart De Strooper, Dirk Daelemans, Philip Van Damme, Ludo Van den Bosch, Catherine Verfaillie

Summary: In this study, we identified NEK6 as a novel therapeutic target for C9orf72 FTD/ALS by performing a kinome-wide CRISPR/Cas9 knock-out screen in human induced pluripotent stem cell-derived cortical neurons. NEK6 was found to regulate poly(PR)-mediated p53-related DNA damage.

ALZHEIMERS & DEMENTIA (2023)

Article Neurosciences

LATE-NC aggravates GVD-mediated necroptosis in Alzheimer's disease

Marta J. Koper, Sandra O. Tome, Klara Gawor, Annelies Belet, Evelien Van Schoor, Jolien Schaeverbeke, Rik Vandenberghe, Mathieu Vandenbulcke, Estifanos Ghebremedhin, Markus Otto, Christine A. F. von Arnim, Sriram Balusu, Matthew B. Blaschko, Bart De Strooper, Dietmar Rudolf Thal

Summary: Alzheimer's Disease (AD) is not only linked to its hallmark lesions, but also to other co-occurring pathologies. The presence of phosphorylated transactive-response DNA binding protein 43 (pTDP-43) and granulovacuolar degeneration (GVD) are co-pathologies associated with AD. This study investigated the impact of LATE-NC on the severity of necroptosis-associated GVD lesions, phosphorylated tau (pTau) pathology, and neuronal density. The results suggest that the presence of LATE-NC in AD contributes to necroptosis pathway activation, leading to an accelerated neuronal demise.

ACTA NEUROPATHOLOGICA COMMUNICATIONS (2022)

Article Clinical Neurology

Pyroptosis in Alzheimer's disease: cell type-specific activation in microglia, astrocytes and neurons

Sebastiaan Moonen, Marta J. Koper, Evelien Van Schoor, Jolien M. Schaeverbeke, Rik Vandenberghe, Christine A. F. von Arnim, Thomas Tousseyn, Bart De Strooper, Dietmar Rudolf Thal

Summary: The study investigated the contribution of pyroptosis, a pro-inflammatory mechanism of cell death downstream of the inflammasome, to neurodegeneration in Alzheimer's disease (AD). The findings suggest the activation of pyroptosis in specific cell types and its potential link to neuron death in AD.

ACTA NEUROPATHOLOGICA (2023)

Article Biochemistry & Molecular Biology

Antibody-mediated inhibition of tissue-type plasminogen activator binding to the low-density lipoprotein receptor-related protein 1 as a potential beneficial modulator for stroke therapy

Philip H. H. Klecker, Laura Fritzen, Alexander D. D. Mazura, Sascha Weggen, Claus U. U. Pietrzik

Summary: The preferred therapy for acute ischemic stroke is the use of Alteplase, a drug containing the enzyme tPA which destabilizes blood clots. BBB breakdown, associated with TJ protein degradation, is a significant issue in stroke pathology and appears to be more severe during therapy. The exact mechanisms of how tPA causes BBB breakdown are not fully understood, but it is believed that interaction with LRP1 is necessary for this effect. This study found that tPA does not change the barrier properties of microvascular endothelial cells but does affect microglial activation and BBB breakdown.

JOURNAL OF CELLULAR BIOCHEMISTRY (2023)

Article Biology

Brain Region-Specific Differences in Amyloid-β Plaque Composition in 5XFAD Mice

Angelika Sabine Bader, Marius-Uwe Gnaedig, Merle Fricke, Luca Bueschgens, Lena Josefine Berger, Hans-Wolfgang Klafki, Thomas Meyer, Olaf Jahn, Sascha Weggen, Oliver Wirths

Summary: Senile plaques consisting of amyloid-beta (A beta) peptides are a major pathological hallmark of Alzheimer's disease (AD). A beta 1-40 and A beta 1-42 are considered canonical full-length A beta species. In 5XFAD mice, overall plaque load increased in the subiculum, hippocampus, and cortex, with the subiculum having the highest plaque coverage. The load of A beta 1-x peaked at five months and decreased thereafter in the subiculum, while plaques positive for truncated A beta 4-x species increased continuously over time. We hypothesize ongoing plaque remodeling leads to conversion of A beta 1-x peptides into A beta 4-x peptides in brain regions with high A beta plaque burden.

LIFE-BASEL (2023)

Article Chemistry, Medicinal

Discovery of brain permeable 2-Azabicyclo[2.2.2]octane sulfonamides as a novel class of presenilin-1 selective γ-secretase inhibitors

Rajeshwar Narlawar, Lutgarde Serneels, Celia Gaffric, Harrie J. M. Gijsen, Bart De Strooper, Francois Bischoff

Summary: This paper describes the rational design, synthesis, structure-activity relationship (SAR), and biological profile of selective gamma-secretase inhibitors for presenilin-1 (PSEN-1) complex. The study analyzes known inhibitors to understand the characteristics required for selective inhibition, and uses this knowledge to design and synthesize a new class of brain-penetrant inhibitors. The compound (+)-13b shows high potency and selectivity towards PSEN1-APH1B complex, making it a promising candidate for further lead optimization.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2023)

Article Multidisciplinary Sciences

MEG3 activates necroptosis in human neuron xenografts modeling Alzheimer's disease

Sriram Balusu, Katrien Horre, Nicola Thrupp, Katleen Craessaerts, An Snellinx, Lutgarde Serneels, Dries T'Syen, Iordana Chrysidou, Amaia M. Arranz, Annerieke Sierksma, Joel Simren, Thomas K. Karikari, Henrik Zetterberg, Wei-Ting Chen, Dietmar Rudolf Thal, Evgenia Salta, Mark Fiers, Bart De Strooper

Summary: Neuronal cell loss is a defining feature of Alzheimer's disease (AD), and this study reveals that the up-regulation of long noncoding RNA MEG3 is strongly associated with AD. The overexpression of MEG3 induces necroptosis in human neurons, leading to significant neuronal cell loss. However, down-regulating MEG3 or inhibiting necroptosis could rescue neuronal cell loss in a mouse model of AD, suggesting potential therapeutic approaches for AD.

SCIENCE (2023)

Review Neurosciences

Microglia states and nomenclature: A field at its crossroads

Rosa C. Paolicelli, Amanda Sierra, Beth Stevens, Marie-Eve Tremblay, Adriano Aguzzi, Bahareh Ajami, Ido Amit, Etienne Audinat, Ingo Bechmann, Mariko Bennett, Frederick Bennett, Alain Bessis, Knut Biber, Staci Bilbo, Mathew Blurton-Jones, Erik Boddeke, Dora Brites, Bert Brone, Guy C. Brown, Oleg Butovsky, Monica J. Carson, Bernardo Castellano, Marco Colonna, Sally A. Cowley, Colm Cunningham, Dimitrios Davalos, Philip L. De Jager, Bart de Strooper, Adam Denes, Bart J. L. Eggen, Ukpong Eyo, Elena Galea, Sonia Garel, Florent Ginhoux, Christopher K. Glass, Ozgun Gokce, Diego Gomez-Nicola, Berta Gonzalez, Siamon Gordon, Manuel B. Graeber, Andrew D. Greenhalgh, Pierre Gressens, Melanie Greter, David H. Gutmann, Christian Haass, Michael T. Heneka, Frank L. Heppner, Soyon Hong, David A. Hume, Steffen Jung, Helmut Kettenmann, Jonathan Kipnis, Ryuta Koyama, Greg Lemke, Marina Lynch, Ania Majewska, Marzia Malcangio, Tarja Malm, Renzo Mancuso, Takahiro Masuda, Michela Matteoli, Barry W. McColl, Veronique E. Miron, Anna Victoria Molofsky, Michelle Monje, Eva Mracsko, Agnes Nadjar, Jonas J. Neher, Urte Neniskyte, Harald Neumann, Mami Noda, Bo Peng, Francesca Peri, V. Hugh Perry, Phillip G. Popovich, Clare Pridans, Josef Priller, Marco Prinz, Davide Ragozzino, Richard M. Ransohoff, Michael W. Salter, Anne Schaefer, Dorothy P. Schafer, Michal Schwartz, Mikael Simons, Cody J. Smith, Wolfgang J. Streit, Tuan Leng Tay, Li-Huei Tsai, Alexei Verkhratsky, Rommy von Bernhardi, Hiroaki Wake, Valerie Wittamer, Susanne A. Wolf, Long-Jun Wu, Tony Wyss-Coray

Summary: Microglial research has made significant progress, but the current classification system fails to accurately describe their diversity, leading to misconceptions about their functions. To address this issue, a group of multidisciplinary experts has proposed a naming framework and recommendations to help researchers better understand and describe the different states and functions of microglia.

NEURON (2022)

Letter Clinical Neurology

Diabetes and Alzheimer's disease: shared genetic susceptibility?

John Hardy, Bart de Strooper, Valentina Escott-Price

LANCET NEUROLOGY (2022)

暂无数据